Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
kmFhu71kxpaHj7Q3
Listen
